Z Squared Inc. heads into its July 2 earnings event with the borrow market now functionally closed — a meaningful tightening even from the already-constrained levels described in the June 24 preview.
Since that earlier article, conditions have deteriorated further. Availability has collapsed from roughly 11% to just 0.46% — the lowest reading in the stock's tracked history, meaning virtually every share in the lending pool is already out on loan. Cost to borrow has nearly doubled over the same period, jumping from 23.4% to 43.7%, its highest recorded level. Short interest has accelerated in lockstep: the estimated short position has more than doubled over the past week alone, up 133% on the week and roughly 418% over the past month. What was already a punishing environment for bears has become materially worse in the six days since the last preview.
The stock itself adds a volatile backdrop to that setup. ZSQR closed at $12.46, down 25.5% on the week, recovering only modestly from what appears to have been a sharp pullback from the mid-$16 range. The month-over-month gain still stands at 31.6%, so longs who bought a month ago remain in the money — but anyone who chased the peak is now underwater. That combination of a falling price and rising short interest in a near-zero-availability environment is the precise mechanics of a crowded, expensive short position that becomes increasingly unstable the more the stock moves in either direction.
The only prior earnings data point shows ZSQR fell 4.7% in the session after its May 15 report and slid a further 8.7% over the following five days — a pattern that would ordinarily embolden bears. But the lending market in May looked nothing like it does now: cost to borrow was around 6-7% and availability was meaningful. Short sellers who were wrong last time had an easier exit. With availability now at a near-total lockout and cost to borrow at 43.7%, the asymmetry of a forced cover on an adverse move is far more pronounced than it was six weeks ago.
The July 2 print will test whether the biotech's results can justify a stock that has tripled in a month — or whether a disappointing release triggers a cover scramble in a lending market with almost no room to manoeuvre.
See the live data behind this article on ORTEX.
Open ZSQR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
